Home ›
Data Desk › Starling Oncology Inc.: Form 25-NSE filed to end a listing
MarginsX Data Desk · Delistings · Oncology · Debt financing
Starling Oncology Inc.: Form 25-NSE filed to end a listing
On Nov 13, 2026 a Form 25-NSE was filed to take a class of Starling Oncology Inc. (STLN) securities off an exchange. (SEC EDGAR, 25-NSE, Nov 13, 2026)
By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.
The stock
The Nasdaq screener puts its market value at $357.0M. (Nasdaq stock screener, Nov 13, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/STLN)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.
Facts behind this article
| Fact | Value | Source | As of |
|---|
| Name | Starling Oncology Inc. | Source | 2026-11-13 |
| Form | 25-NSE | Source | 2026-11-13 |
| Filed | Nov 13, 2026 | Source | 2026-11-13 |
| Who | Starling Oncology Inc. (STLN) | Source | 2026-11-13 |
| Symbol | STLN | Source | 2026-11-13 |
| Cap | 356,968,584 USD | Source | 2026-11-13 |
Sources
Automated from SEC filings and market data. No AI. For information only. Not investment advice.
Discuss in MarginsX More from the Data Desk
More on MarginsX
Companies in this article
Topics
Related Data Desk stories
Every Data Desk article: /desk · RSS